Total Payments
$250,579
2024 Payments
$3,740
Companies
46
Transactions
1,845
Medicare Patients
25,889
Medicare Billing
$22.3M
Payment Breakdown by Category
Research$204,591 (81.6%)
Food & Beverage$29,190 (11.6%)
Consulting$9,675 (3.9%)
Travel$4,207 (1.7%)
Other$2,700 (1.1%)
Education$216.18 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $204,591 | 42 | 81.6% |
| Food and Beverage | $29,190 | 1,778 | 11.6% |
| Consulting Fee | $9,675 | 5 | 3.9% |
| Travel and Lodging | $4,207 | 11 | 1.7% |
| Honoraria | $2,700 | 1 | 1.1% |
| Education | $216.18 | 8 | 0.1% |
Payments by Type
Research
$204,591
42 transactions
General
$45,988
1,803 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $172,891 | 15 | $0 (2023) |
| Celgene Corporation | $27,758 | 31 | $0 (2019) |
| Amgen Inc. | $14,703 | 291 | $0 (2024) |
| Horizon Therapeutics plc | $5,259 | 158 | $0 (2023) |
| ABBVIE INC. | $4,792 | 155 | $0 (2024) |
| UCB, Inc. | $4,501 | 221 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,855 | 92 | $0 (2024) |
| GlaxoSmithKline, LLC. | $2,398 | 82 | $0 (2024) |
| Gilead Sciences, Inc. | $2,302 | 11 | $0 (2020) |
| Janssen Research & Development, LLC | $1,728 | 10 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,740 | 219 | Amgen Inc. ($1,103) |
| 2023 | $6,467 | 214 | ABBVIE INC. ($2,249) |
| 2022 | $6,407 | 215 | UCB, Inc. ($1,744) |
| 2021 | $3,287 | 190 | Horizon Therapeutics plc ($634.03) |
| 2020 | $5,884 | 209 | Gilead Sciences, Inc. ($2,302) |
| 2019 | $36,394 | 314 | Celgene Corporation ($18,640) |
| 2018 | $70,047 | 237 | AstraZeneca UK Limited ($65,347) |
| 2017 | $118,353 | 247 | AstraZeneca UK Limited ($106,299) |
All Payment Transactions
1,845 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/10/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $27.81 | General |
| Category: Bone Health | ||||||
| 12/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $6.14 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $1.00 | General |
| Category: Immunology | ||||||
| 12/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Immunology | ||||||
| 12/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $1.27 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $0.95 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $0.74 | General |
| Category: Immunology | ||||||
| 11/14/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $21.22 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.05 | General |
| 11/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Immunology | ||||||
| 11/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE | AstraZeneca UK Limited | $112,551 | 2 |
| The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus | AstraZeneca UK Limited | $59,095 | 4 |
| A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus (CC-220-SLE-001) | Celgene Corporation | $18,518 | 1 |
| CC-220-SLE-001 | Celgene Corporation | $8,770 | 1 |
| A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. | Gilead Sciences, Inc. | $2,302 | 11 |
| A PHASE I/II, OPEN-LABEL, PARALLEL-GROUP, DOSE ESCALATION AND EXPANSIO | GlaxoSmithKline, LLC. | $1,346 | 9 |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | AbbVie Inc. | $1,036 | 7 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | AbbVie Inc. | $973.47 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 48 | 6,846 | 629,428 | $22.3M | $5.6M |
| 2022 | 47 | 6,811 | 500,761 | $19.0M | $5.2M |
| 2021 | 48 | 6,770 | 476,369 | $18.8M | $5.7M |
| 2020 | 52 | 5,462 | 473,298 | $18.8M | $5.9M |
Total Patients
25,889
Total Services
2,079,856
Medicare Billing
$22.3M
Procedure Codes
195
All Medicare Procedures & Services
195 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 66 | 40,500 | $3.8M | $1.4M | 35.4% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 99 | 340,000 | $5.9M | $1.3M | 22.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 92 | 101,220 | $2.7M | $803,793 | 29.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 343 | 32,700 | $1.5M | $602,765 | 40.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 37 | 28,850 | $2.2M | $304,014 | 14.0% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 24 | 64,043 | $1.1M | $300,183 | 27.6% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 14 | 3,900 | $780,000 | $247,678 | 31.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 466 | 2,727 | $1.0M | $150,137 | 14.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 155 | 1,034 | $796,110 | $101,781 | 12.8% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 13 | 3,751 | $824,340 | $98,168 | 11.9% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 319 | 2,541 | $210,405 | $44,189 | 21.0% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 419 | 926 | $325,952 | $38,159 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 257 | 333 | $117,549 | $29,032 | 24.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 146 | 146 | $100,740 | $23,365 | 23.2% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 381 | 381 | $167,170 | $18,791 | 11.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 728 | 1,731 | $60,555 | $14,468 | 23.9% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 233 | 471 | $67,353 | $12,914 | 19.2% |
| 82306 | Vitamin d-3 level | Office | 2023 | 328 | 391 | $47,311 | $11,269 | 23.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 276 | 286 | $40,898 | $6,941 | 17.0% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Office | 2023 | 174 | 179 | $39,350 | $6,680 | 17.0% |
| 86225 | Measurement of dna antibody, native or double stranded | Office | 2023 | 319 | 363 | $27,951 | $4,839 | 17.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 33 | 204 | $112,200 | $4,310 | 3.8% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 75 | 122 | $17,446 | $4,305 | 24.7% |
| 86226 | Measurement of dna antibody, single stranded | Office | 2023 | 319 | 363 | $23,958 | $4,264 | 17.8% |
| 86038 | Screening test for autoimmune disorder | Office | 2023 | 319 | 363 | $23,908 | $4,257 | 17.8% |
About Dr. Vipul Joshi, MD
Dr. Vipul Joshi, MD is a Specialist healthcare provider based in Brandon, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003868993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vipul Joshi, MD has received a total of $250,579 in payments from pharmaceutical and medical device companies, with $3,740 received in 2024. These payments were reported across 1,845 transactions from 46 companies. The most common payment nature is "" ($204,591).
As a Medicare-enrolled provider, Joshi has provided services to 25,889 Medicare beneficiaries, totaling 2,079,856 services with total Medicare billing of $22.3M. Data is available for 4 years (2020–2023), covering 195 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Brandon, FL
- Active Since 05/17/2006
- Last Updated 10/14/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1003868993
Products in Payments
- CC-220 (Drug) $27,288
- EVENITY (Biological) $7,250
- KRYSTEXXA (Biological) $4,855
- Cimzia (Drug) $3,090
- RINVOQ (Biological) $2,918
- SAPHNELO (Biological) $2,272
- Enbrel (Biological) $1,869
- XELJANZ (Drug) $1,383
- Actemra (Biological) $1,238
- ORENCIA (Biological) $1,212
- RAYOS (Drug) $1,052
- Prolia (Biological) $1,047
- BENLYSTA (Biological) $1,035
- Humira (Biological) $952.06
- SIMPONI ARIA (Biological) $906.27
- COSENTYX (Biological) $831.57
- Tymlos (Biological) $681.97
- ACTHAR (Biological) $670.71
- COSENTYX (Drug) $460.66
- Rituxan (Biological) $458.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Brandon
Mr. Francis Caban, M.d, M.D
Specialist — Payments: $42,145
Specialist $42,145
Dr. Farrukh Saeed, M.d, M.D
Specialist — Payments: $4,558
Specialist $4,558
Gary Ronay, M.d, M.D
Specialist — Payments: $2,034
Specialist $2,034
Dr. George Dermarkar, M.d, M.D
Specialist — Payments: $1,968
Specialist $1,968
Dr. John Kilgore, M.c, M.C
Specialist — Payments: $1,353
Specialist $1,353
Dr. Stacy Perez, Md, MD
Specialist — Payments: $450.24
Specialist $450.24